Predictive Oncology Inc. (NASDAQ: POAI) Subsidiary Participates in UK 100,000 Genomes Project
The main subsidiary of POAI partnered with Genomics England for the groundbreaking UK 100,000 Genomes Project POAI is positioned on the cutting edge of future cancer treatments The company’s AI-driven platforms are improving cancer patient outcomes and setting a new standard in the industry For years, cancer treatment has involved human beings playing the role of guinea pigs. Oncologists have become quite adept at diagnosing specific types of cancer, but they mostly lack the data to know which drugs will be most effective in fighting patients’ specific cancer types. Patients leave doctors’ offices hopeful but worried, gambling their recovery on…